Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center




VANISH 2- Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2

Not Available
III
Kanagasundram, Arvindh
CRE-CHF0001


DEFINE-HT - DevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation

Not Available
III
Schlendorf, Kelly
CRE-CHF0010



A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension

Not Available
III
Not Available
NCT02910414
CRE-INT0003

The RADIANCE-HTN; Study A study of the ReCor Medical Paradise System in Clinical Hypertension

Not Available
III
Fong, Pete
NCT02649426
CRE-INT0001

A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors

Multiple Cancer Types

This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Neuro-Oncology, Pediatrics
III
Esbenshade, Adam
NCT04939597
COGACCL2031

Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma

Multiple Cancer Types

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Leukemia, Pediatric Leukemia
III
Borinstein, Scott
NCT05602194
VICC-NTPED23475

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.